ANAND ET AL.

Appl. No. 10/563,042

Atty. Ref.: 620-406

Amendment After Final Rejection

July 8, 2011

Page 2

**AMENDMENTS TO THE CLAIMS**:

Please amend the claims as follows:

1. (Previously Presented) A method of treating cancer in an individual

comprising administering an Aurora A kinase inhibitor and a mitotic spindle assembly

inhibitor to said individual, wherein Aurora A kinase is over-expressed in the cancer

cells relative to non-cancer cells.

2. (Previously Presented) A method according to claim 1 wherein said cancer is

resistant to said mitotic spindle assembly inhibitor.

3. (Previously Presented) A method according to claim 1 wherein the mitotic

spindle assembly inhibitor is a taxane.

4. (Previously Presented) A method according to claim 3 wherein the taxane is

paclitaxel or a derivative thereof and wherein said derivative is a taxane.

Claim 5. (Canceled)

6. (Previously Presented) A method according to claim 1 wherein the Aurora A

kinase inhibitor is an antibody molecule which specifically binds to an Aurora A kinase.

7. (Previously Presented) A method according to claim 1 wherein the Aurora A

kinase inhibitor is a sense or anti-sense nucleic acid molecule that inhibits the

expression of an Aurora A kinase.

8. (Previously Presented) A method according to claim 1 wherein the cancer is

an epithelial cancer.

1820504

ANAND ET AL.
Appl. No. 10/563,042
Atty. Ref.: 620-406
Amendment After Final Rejection
July 8, 2011
Page 3

- 9. (Original) A method according to claim 8 wherein the epithelial cancer is skin, thyroid, colon, pancreas, lung, prostate, cervical, ovarian or breast cancer.
- 10. (Withdrawn) A method according to claim 1 wherein the cancer is liver, kidney or brain cancer.

Claims 11-51. (Canceled)